Conventional non-catalytic transformations of an amine with an alcohol take place via installing a suitable leaving group instead of the alcohol functionality followed by nucleophilic substitution; these multistep pathways suffer from low atom economy8 or limited selectivity and the production of stoichiometric amounts of waste (Fig. 1a 9.
Although the concept of data mapping onto pathways is not new and is supported by other pathway resources [ 6, 19, 90] these pathways suffer from a number of issues pertaining to the lack standard graphical notation used to depict them.
Most strains using the XR/XD pathway suffer from low ethanol yield, although an adapted strain using this pathway was recently reported to have a 79% of theoretical ethanol yield from D-xylose [ 28].
The biotin pathway suffers from gene inactivation (missing fabI), although it could still synthesize biotin from 8-amino-7-oxononanoate (KAPA) by action of the bioF gene product, given its supplied with the precursor pimelyl-CoA or KAPA itself.
Engineered heterologous multi-gene metabolic pathways often suffer from flux imbalance and toxic metabolites, as the production host typically lacks the regulatory mechanisms for the heterologous pathway.
Our results suggest that enzyme compartmentalization is a powerful approach for improving the catalytic turnover of a channeled carbon substrate and should be particularly useful when applied to synthetic metabolic pathways that suffer from poor translation efficiency, are present in highly variable copy numbers, and have low turnover for new substrates.
Likewise, loss-of-expression and loss-of-function mutations in HOIL-1 result in a fatal, human, inherited disorder characterized by chronic inflammation; consistent with loss of the major defensive inflammatory signaling pathways, affected patients suffer from invasive bacterial infections (Boisson et al., 2012).
Compared with global procurement, both institutional and consumer markets have less defined advocacy and policy pathways and often suffer from lack of donor funding to continue purchasing the product beyond initial introduction pilots, as they do not have large-scale, committed funding mechanisms behind them.
On the other hand, polymorphic patients in the adrenergic pathway seemed to suffer from clinical disappointment.
It is possible that some patients with diabetes have inactivating mutations in the insulin/IGFI pathway and thus "suffer" from benevolent diabetes.
However, the KEGG pathway database suffers from a number of limitations that reduce the adaptability of the pathways for automated analysis.
